Pitavastatin Calcium

證據等級: L5

預測適應症: 0 個

Pitavastatin Calcium: Drug Repurposing Evaluation — Insufficient Data to Complete Prediction

One-Sentence Summary

Pitavastatin Calcium is a statin-class lipid-lowering agent, clinically established for the management of hypercholesterolaemia and mixed dyslipidaemia through inhibition of HMG-CoA reductase. No TxGNN repurposing predictions were generated for this drug in the current evidence pack, making it impossible to identify or evaluate a candidate new indication. All three major data components — mechanism of action, safety labelling, and product-level NPRA registration details — remain unresolved data gaps; the pipeline must be re-run with complete inputs before a full evaluation can be produced.

Quick Overview

Item	Content
Original Indication	Hypercholesterolaemia / Dyslipidaemia (inferred from drug class; NPRA-specific approved text not retrieved)
Predicted New Indication	— (No TxGNN prediction available in this evidence pack)
TxGNN Prediction Score	—
Evidence Level	— (No prediction to evaluate)
Malaysia Market Status	✓ Marketed
Number of Registrations	3
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN-predicted indication is present in the current evidence pack (predicted_indications array is empty). A structured repurposing rationale cannot be constructed without a target disease.

Based on publicly available information, Pitavastatin Calcium is a synthetic, fully fluorinated statin that competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase — the rate-limiting enzyme in hepatic cholesterol biosynthesis. By reducing intracellular cholesterol, it upregulates LDL receptors, lowers circulating LDL-C and triglycerides, and modestly raises HDL-C. Beyond lipid effects, statins as a class also exert pleiotropic actions including anti-inflammatory, antioxidant, and immunomodulatory effects, properties that have motivated repurposing research in oncology, cardiovascular risk reduction beyond lipid-lowering, and neurodegenerative diseases.

However, all of the above is general class knowledge, not evidence drawn from this evidence pack. The formal mechanism of action data field (original_moa) is flagged as a data gap (severity: High), and no indication-level evidence (clinical trials or literature) has been retrieved. Once TxGNN predictions and supporting evidence are loaded into the pack, a complete mechanism-to-indication alignment analysis can be performed.

Clinical Trial Evidence

Currently no related clinical trials registered — no predicted indication is available in this evidence pack to query against.

Literature Evidence

Currently no related literature available — no predicted indication is available in this evidence pack to query against.

Malaysia Market Information

The evidence pack records 3 registered products in Malaysia, but all product-level detail fields (authorisation number, product name, dosage form, and approved indication text) were not populated during data retrieval. The table below reflects the state of the data as received.

Authorization Number	Product Name	Dosage Form	Approved Indication
Not retrieved	Not retrieved	Not retrieved	Not retrieved
Not retrieved	Not retrieved	Not retrieved	Not retrieved
Not retrieved	Not retrieved	Not retrieved	Not retrieved

Note: NPRA product registration details should be retrieved directly from the NPRA Quest 3+ portal or via package insert PDF parsing to populate these fields.

Safety Considerations

Please refer to the package insert for safety information.

All safety fields — key warnings, contraindications, and drug-drug interactions — are flagged as data gaps in this evidence pack. The blocking data gap (DG001) indicates that TFDA/NPRA package insert PDFs have not yet been downloaded and parsed. This must be resolved before any safety-based prescribing or repurposing decision can be made.

Conclusion and Next Steps

Decision: Hold

Rationale: The evidence pack for Pitavastatin Calcium contains no TxGNN repurposing predictions and is missing all three critical data layers (MOA, safety labelling, and NPRA product details); no repurposing candidate can be evaluated, scored, or recommended at this stage.

To proceed, the following is needed:

Re-run TxGNN prediction pipeline with Pitavastatin Calcium correctly mapped to its DrugBank ID (DB08860) so that predicted_indications is populated with candidate diseases, scores, and supporting evidence
Resolve DrugBank data gap (DG002): Query the DrugBank API using DrugBank ID DB08860 to retrieve the full drug profile including pharmacology, MOA, drug categories, and toxicity data
Resolve NPRA/TFDA package insert data gap (DG001): Download and parse the product insert PDFs from the NPRA portal or TFDA website to populate key warnings, contraindications, approved indication texts per registration, and drug interaction data
Populate NPRA licence details: Re-query the NPRA Quest 3+ database to retrieve authorisation numbers, product names, dosage forms, and manufacturers for all 3 registered products
Re-generate evidence pack once the above gaps are resolved, then produce a full evaluation report with a defined target indication, evidence level, and Go/Proceed/Hold recommendation grounded in actual data
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.